Compare Lamb Weston Holdings Inc (LW) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs TransMedics Group Inc — how do they compare? Lamb Weston Holdings Inc trades at $47.87 (market cap $6.81B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Lamb Weston Holdings Inc is far larger — about 2.5× TransMedics Group Inc's market cap, and Lamb Weston Holdings Inc pays a 3.07% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and TransMedics Group Inc for 24 Days on average.
| LW | TMDX | |
|---|---|---|
Market Cap | $6.81B | $2.74B |
Volume | 4,638,686 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $150.42 |
52-Week Low | $38.48 | $61.99 |
Typical Hold Time | 66 Days | 24 Days |
Enterprise Value | $10.61B | $3.13B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $49.46, up 2.85% today, showing strong momentum with four consecutive earnings beats. The stock maintains a bullish technical signal with support at $49 and resistance at $50. Fundamentals show solid revenue growth from $4.1B in 2022 to $6.45B in 2025, though net margins compressed from 18.85% to 3.85%. Analyst consensus is mixed with 31.58% Buy ratings and a $53.71 price target, representing 8.6% upside potential.
LW offers potential through continued earnings outperformance and margin recovery initiatives, but faces risks from profit margin volatility and ongoing legal scrutiny. The stock's current valuation at 27x P/E appears reasonable given growth prospects, though investors should monitor execution on the Focus to Win cost-saving strategy and resolution of fiduciary investigation concerns.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
